Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials
Christine B Turley,LaKesha Tables,Trevon Fuller,Lisa J Sanders,Hyman Scott,Amaran Moodley,Amanda Woodward Davis,Brett Leav,Jacqueline Miller,Kathryn Schoemaker,An Vandebosch,Jerald Sadoff,Wayne Woo,Iksung Cho,Lisa M Dunkle,Sijia Li,Lars van der Laan,Peter B Gilbert,Dean Follmann,Holly Jaynes,James G Kublin,Lindsey R Baden,Paul Goepfert,Karen Kotloff,Cynthia L Gay,Ann R Falsey,Hana M El Sahly,Magdalena E Sobieszczyk,Yunda Huang,Kathleen M Neuzil,Lawrence Corey,Beatriz Grinsztejn,Glenda Gray,Nadine Rouphael,Alex Luedtke,COVID-19 Prevention Network CoVPN
DOI: https://doi.org/10.1016/j.vaccine.2023.06.066
IF: 4.169
2023-07-25
Vaccine
Abstract:Questions remain regarding the effect of baseline host and exposure factors on vaccine efficacy (VE) across pathogens and vaccine platforms. We report placebo-controlled data from four Phase 3 COVID-19 trials during the early period of the pandemic. This was a cross-protocol analysis of four randomized, placebo-controlled efficacy trials (Moderna/mRNA1273, AstraZeneca/AZD1222, Janssen/Ad26.COV2.S, and Novavax/NVX-CoV2373) using a harmonized design. Trials were conducted in the United States and international sites in adults ≥ 18 years of age. VE was assessed for symptomatic and severe COVID-19. We analyzed 114,480 participants from both placebo and vaccine arms, enrolled July 2020 to February 2021, with follow up through July 2021. VE against symptomatic COVID-19 showed little heterogeneity across baseline socio-demographic, clinical or exposure characteristics, in either univariate or multivariate analysis, regardless of vaccine platform. Similarly, VE against severe COVID-19 in the single trial (Janssen) with sufficient endpoints for analysis showed little evidence of heterogeneity. COVID-19 VE is not influenced by baseline host or exposure characteristics across efficacy trials of different vaccine platforms and countries when well matched to circulating virus strains. This supports use of these vaccines, regardless of platform type, as effective tools in the near term for reducing symptomatic and severe COVID-19, particularly for older individuals and those with common co-morbidities during major variant shifts. Clinical trial registration numbers: NCT04470427, NCT04516746, NCT04505722, and NCT04611802.